拉坦前列腺素(游离酸)
| 中文名称 | 拉坦前列腺素(游离酸) |
|---|---|
| 中文同义词 | 拉坦前列素自由酸;拉坦前列腺素相关物质E;拉坦前列腺素(游离酸);拉坦前列素(游离酸);拉坦前列素有关物质E;拉坦前列腺素相关物质E USP标准品;拉坦前列素相关化合物E;拉坦前列素相关杂质E |
| 英文名称 | Latanoprost acid |
| 英文同义词 | LATANOPROST (FREE ACID);LAT-FA;17-PHENYL-13,14-DIHYDRO TRINOR PROSTAGLANDIN F2ALPHA;(5Z,9ALPHA,11ALPHA,15R)-9,11,15-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5-EN-1-OIC ACID;9ALPHA, 11ALPHA, 15R-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROST-5Z-EN-1-OIC ACID;PHXA 85;PhXA 85, (5Z,9α,11α,15R)-9,11,15-Trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oic acid;Latanoprost acid,(5Z,9α,11α,15R)-9,11,15-Trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oic acid, PhXA 85 |
| CAS号 | 41639-83-2 |
| 分子式 | C23H34O5 |
| 分子量 | 390.51 |
| EINECS号 | |
| 相关类别 | 中间体;合成;标准品;Aromatics, Chiral Reagents, Metabolites & Impurities, Pharmaceuticals, Intermediates & Fine Chemicals;Aromatics;Chiral Reagents;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals |
| Mol文件 | 41639-83-2.mol |
| 结构式 |  |
拉坦前列腺素(游离酸) 性质
| 沸点 | 609.1±50.0 °C(Predicted) |
|---|---|
| 密度 | 1.159±0.06 g/cm3(Predicted) |
| 储存条件 | -20°C |
| 溶解度 | DMSO：易溶 |
| 酸度系数(pKa) | 4.76±0.10(Predicted) |
| 形态 | 油状 |
| 颜色 | 淡黄色 |
| 稳定性 | 吸湿性 |
Latanoprost acid 是前列腺素 (PG) F2α 的类似物，是选择性的前列腺素受体 FP 激动剂，FP 可以特异性激活 FP-PG 受体。Latanoprost acid 通过抑制 ERK，AKT，JNK 和 p38 级联反应，继而沿 c-fos/NFATc1 通路抑制 RANKL 诱导的破骨细胞生成和功能。Latanoprost acid 是一种可降低眼内压力的药物。
|
FP
|
Latanoprost acid (10-20 μM;24 hours) reduces he protein expressions of c-fos and NFATc1.
Latanoprost acid (10μM with 50ng/ml RANKL) significantly inhibits ERK, p38, AKT and JNK.
Latanoprost acid (10 μM, 20 μM) significantly inhibits the mature osteoclast formation.
Western Blot Analysis
| Cell Line: | Bone marrow-derived macrophages cells (BMMs) |
| Concentration: | 10 μM, 20 μM |
| Incubation Time: | 24 hours |
| Result: | Reduced he protein expressions of c-fos and NFATc1. |
Latanoprost acid (i.p.; 20 mg/kg; once a day for 7 days) notably prevents LPS-induced bone destruction at a dose of 20mg/kg.
| Animal Model: | 8-week-old C57BL/6J mice |
| Dosage: | 20 mg/kg |
| Administration: | Intraperitoneally injected; once a day for 7 days |
| Result: | Notably prevented LPS-induced bone destruction at a dose of 20mg/kg. |
安全信息
| WGK Germany | 3 |
|---|---|
| 海关编码 | 2937500000 |
| 提供商 | 语言 |
|---|---|
|
英文
|
下游产品